Lincoln Pharmaceuticals Ltd · NSE:LINCOLN
Lincoln Pharmaceuticals — Q3 FY2023 Earnings Presentation
24 slides from Lincoln Pharmaceuticals's earnings presentation, 2023
Slide 1: Q3 FY2023 Earnings Presentation
Q3 FY2023 PHARMACEUTICALS LTD Earnings Presentation HEALTHCARE FOR ALL GROWING IS COMMITEMENT. WE PROCESS. www.lincolnpharma.com
Slide 2: Safe Harbour
SAFEHARBOUR This presentation contains statements that contain “forward looking statements” including, but without limitation, statements relating to the implementation of strategic initiatives, and other statements relat- ing to Lincoln Pharmaceuticals’ future business developments and economic per
Slide 3: Corporate Overview
CORPORATEOVERVIEW Background Product Portfolio Manufacturing Exports Established in the year 1979, 1700 registered productsand Manufacturing facility at Exports increased to 56% in FY22 Lincoln Pharma hasdeveloped another 700 in pipeline. Khatraj and Mehsana, Gujarat. from 11% in FY13. 600+ formulat
Slide 4: Q3FY23 Business Performance & Future Road Map
Q3FY23 BUSINESS PERFORMANCE&FUTUREROAD MAP • Company has reported Net Profit of Rs. 21.61 crore, EBITDA of Rs. 33.11 crore and Total income of Rs. 140.12 crore for the Q3FY23. Company has successfully completed multiple expansion &acquisition of Cephalosporin plant in recent times. • Export Segment
Slide 5: Q3FY23 Standalone Results
Q3FY23 STANDALONERESULTS TOTAL INCOME EBITDA NET PROFIT 122.5 146.3 140.1 26.1 34.6 33.1 17.6 23.7 21.6 Q3FY22 Q2FY23 Q3FY23 Q3FY22 Q2FY23 Q3FY23 Q3FY22 Q2FY23 Q3FY23 Fig (RsCr) Q3 FY2023 Earning Presentation
Slide 6: Performance - Focused Therapeutic Areas
PERFORMANCE - FOCUSED THERAPEUTICAREAS Therapy Area Q3 FY23 Q3 FY22 23.9% General Anti Infectives 23.5% 23.9% 23.5% 24.8% 24.6% Respiratory Systems 8.9% 11.4% Alimentary Tract andMetabolism 6.7% 9.6% Genito Urinary System and Sex Hormones 1.2% 1.4% Musculo-Skeletal System 14.2% 15.2% Q3 FY23 0.9% Q3
Slide 7: Performance Overview
PERFORMANCE OVERVIEW STANDALONE FINANCIAL PERFORMANCE (Rs in Cr.) PARTICULARS Q3 Y-o-Y 9 Months Y-o-Y FY2023 FY2022 Growth (%) FY2023 FY2022 Growth (%) Total Income 140.1 122.5 14.4% 416.4 377.6 10.3% EBITDA 33.1 26.1 26.9% 91.1 86.1 5.8% Margin (%) 23.6% 21.3% 21.9% 22.8% Profit BeforeTax 30.5 23.6
Slide 8: About Lincoln Pharmaceuticals Ltd
ABOUT LINCOLN PHARMACEUTICALS LTD Providing Affordable And Innovative Medicines For Healthier Lives. VISION To spark a universal attempt to uncover cures of diseases by focused and targeted R&D, through forging strategic alliances both domestically and internationally. MISSION Focused on delivering
Slide 9: Key Milestones
KEYMILESTONES 1979 1996/97 2010/11 2016/17 Listed on NSE. Domestic marketexpan- Installed windmill 2.1 Launched nextgeneration Received WHO-GMPfor sion; covered 80% of MW in addition to 6000 progesterone therapy - plant/production unit. India market. KVA in 2009. ProlinSpray. Lincoln was Launched IP
Slide 10: Growth Drivers - Ready for the Next Leap
GROWTHDRIVERS -READY FOR THENEXT LEAP CAPEX Company has completed expansion for launching Cephalosporin products at Mehsana, Gujarat. During the year, company received an approval from WHO-GMP for Tablet Capsule, dry-powder Suspension products for this plant. Production from this plant is expected t
Slide 11: Lincoln Pharmaceuticals Ltd - Financial Overview
LINCOLN PHARMACEUTICALS LTD - FINANCIAL OVERVIEW Year Revenue EBITDA Net Profit EPS ROCE Share Price FY 22 472.1 105.5 69.4 34.6 21.9% 311 FY 12 175.5 16.9 5.1 3.1 10.0% 25.5 10Yrs CAGR 10.4% 20.1% 30% 27.1% 1190 bps 28.4% Book Yalue (Per Share) Market Cap (Rs Cr) Net Debt (Rs Cr) 112 135 157 188 21
Slide 12: Business Revenue-Mix
BUSINESS REVENUE-MIX Particulars (Rs.CR) FY 2013 % FY 2017 % FY 2022 % Domestic Sales 145.03 74.50% 246.6 64.70% 205.90 43.60% Export 49.67 25.50% 119.27 32.60% 266.18 56.40% FY13 FY17 FY22 25.50% 32.60% 56.40% 43.60% 67.40% 74.50% DOMESTIC SALES EXPORT Q3 FY2023 EarningPresentation
Slide 13: Global Footprints
GLOBALFOOTPRINTS Presence over 60+ countries in Europe, Latin America, Africa, Asia Pacific, South EastAsia, and 26 states across India. Srinagar Jammu Chandigarh Uttrakhand Ambala Europe: Delhi Ghaziabad France. Lucknow Guwahati Jaipur Patna Ranchi Ahmedabad Indore Raipur Nagpur Cuttack Vijayawada
Slide 14: Research & Development
RESEARCH &DEVELOPMENT NDDS Formulations Introduced First Time In India by Lincoln Anti-Fungal VaginaSpray. Diclofenac RectalSpray. Sildenafil Oral Spray. Ondansetron Hydrochloride Oral Spray (DOMI-UP). Paracetamol 1000mg Programmed ReleaseTablet (PA-12). Micronized Progesterone Vaginal Spray (PROLIN
Slide 15: Innovations - Lincoln Pharma
INNOVATIONS - LINCOLN PHARMA Q3 FY2023 EarningPresentation
Slide 16: New Launches - Domestic Market
NEW LAUNCHES- DOMESTIC MARKET Q3 FY2023 EarningPresentation
Slide 17: New Launches - International Markets
NEW LAUNCHES- INTERNATIONAL MARKETS Q3 FY2023 EarningPresentation
Slide 18: Wide Spectrum of Therapeutic Coverage
WIDE SPECTRUMOF THERAPEUTICCOVERAGE Cough &Cold/ Dermatologist Gyneacological Sterile Ophthalmic Gastro Intestinal Anti Allergic/ Preparation Products Eye Drops/ Range Anti-asthmatics Ointment Yitamins/ Anti-bacterial/ Anti-viral/ Analgesic/ Anti -Malarial M inerals/ Otology Anti-fungal Anti-pyretic
Slide 19: Best in Class Facilities - Khatraj, Gujarat
BESTIN CLASS FACILITIES – Khatraj, Gujarat Certification EU-GMP, TGA, WHO-GMP Certified; ISO 9001:2015 Certified. R&D Center Approved by Government of India; Team of 30 plus scientists for R&D. Green Energy Windmill and 1MW Solar Roof installed. Producing 65% of company’s total energy consumption. D
Slide 20: Best in Class Facilities - Mehsana, Gujarat
BESTIN CLASS FACILITIES – Mehsana, Gujarat WHO-GMP Certified; ISO 9001:2015 Certified. Certification Approved Team of 10 plus scientists for R&D. R&D Center Dosage Forms Produced at Unit 3 OSD and Dry Powder Injection Description Size Annual Capacity Unit Tablet (Compression & Coating) 511 lacs Tabl
Slide 21: Financial Highlights
FINANCIAL HIGHLIGHTS TOTALREVENUE NET PROFIT 396.3 428.7 482.1 51.5 62.3 69.4 FY20 FY21 FY22 FY20 FY21 FY22 Fig (RsCr) EBITDA NET WORTH 76.5 92.8 105.5 304.1 366.4 432.9 FY20 FY21 FY22 FY20 FY21 FY22 Q3 FY2023 EarningPresentation
Slide 22: Profitability Ratios
PROFITABILITYRATIOS EBITDA MARGIN PAT MARGIN 19.3% 21.7% 21.9% 13.0% 14.5% 14.4% FY20 FY21 FY22 FY20 FY21 FY22 ROCE RONW 22.0% 22.6% 21.9% 16.9% 17.0% 16.0% FY20 FY21 FY22 FY20 FY21 FY22 Q3 FY2023 Earning Presentation
Slide 23: Share Holding Information
SHARE HOLDINGINFORMATION Particulars December 2022 March 2022 Investor Category No of Shareholders No of Shares Held Holding (%) No ofShareholders No of Shares Held Holding (%) Promoter Group 29 92,80,812 46.34% 29 84,22,173 42.05% Public Holding 29,817 1,07,48,916 53.66% 32,418 1,16,07,555 57.95% T
Slide 24: Location
LOCATION Corporate Office Lincoln House B/h Satyam Complex, Science City Road, Sola Ahmedabad - 380060,Gujarat, India. Phone: +91 - 79 - 4107 8000 l Fax: +91- 79 - 4107 8062 Email: info@lincolnpharma.com Web: www.lincolnpharma.com CIN: L24230GJ1995PLC024288 Darshit Shah Gopal Modi CFO, Lincoln Pharm
Lincoln Pharmaceuticals — Q3 FY2023 Earnings Presentation on 6ix